MSD France in the news

A Dutch court has banned the sale of the subcutaneous version of Merck MSD's cancer drug Keytruda in France and other European countries due to patent infringement.

A Dutch court ordered MSD to cease manufacturing and selling its subcutaneous Keytruda in eight European markets due to patent infringement claims by Halozyme Therapeutics.

MSD secured FDA approval for an oral cholesterol-lowering drug, and both MSD and Gilead are progressing with a weekly oral HIV treatment.

The Hague court rejected Halozyme's bid for a preliminary injunction against MSD over the subcutaneous version of Keytruda, citing the lack of a binding undertaking from MSD.

Intervet is building an 11,000 m2 logistics warehouse in Normandy to support its animal health pharmaceutical production plant in Igoville.

MSD France's parent company, Merck, is investing 42 million euros in French research and establishing the MSDAVENIR fund.

Merck faced scrutiny for its strategies to keep Keytruda, its blockbuster anti-cancer drug, expensive and inaccessible to many cancer patients worldwide, despite its life-saving potential.

MSD Animal Health is emphasizing intradermal vaccination for pigs in France, offering needle-free injectors to improve animal welfare and herd health by reducing disease transmission.

MSD Animal Health is expanding its intradermal swine vaccination options, emphasizing improved herd health and farmer convenience, and offers a subsidized injector rental program.

MSD Animal Health is focusing on intradermal vaccination for pigs in France, promoting its benefits for animal welfare, farmer comfort, and disease prevention, and offering a rental program for its needle-free injector.

MSD invests $6.7 billion in Terns Pharmaceuticals to acquire a promising chronic myeloid leukemia treatment, strengthening its pipeline ahead of Keytruda's patent expiry.

Merck is acquiring oncology specialist Terns Pharmaceuticals for $6.7 billion to expand its hematology presence with TERN-701, a treatment for chronic myeloid leukemia.

Merck posted strong Q4 revenue growth driven by oncology and animal health despite net profit falling due to restructuring, with positive full-year 2025 results and optimistic 2026 projections.

Merck is restructuring its human health business into two specialized units to manage an expanding pipeline of over 20 potential blockbuster drugs.

Nearly 40% of unvaccinated young adults aged 18-26 are unaware of the HPV vaccine, with low risk perception and reliance on healthcare professionals for vaccination decisions.

Keytruda's global sales reached $32 billion, making it the most expensive drug for French health insurance and a pioneer in immunotherapy.

France quickly ordered and deployed MSD-produced vaccines to control the 2025 outbreak of contagious nodular dermatitis in cattle, vaccinating over a million animals.

MSD Animal Health produces and rapidly supplies vaccines for contagious nodular dermatitis to France, with capacity to scale up if needed, though full herd vaccination would take months.

Halozyme secured a German injunction blocking MSD from selling Keytruda SC due to alleged patent infringement on subcutaneous administration technology.

Novo Nordisk and J&J failed in Alzheimer's drug trials, while AstraZeneca and Pfizer/MSD gained FDA approvals for cancer treatments.